Plasma lipids and lipoprotein reference values, and the prevalence of dyslipoproteinemia in Canadian adults

Canadian Journal of Cardiology

Volumn 15, Issue 4, 1999, Pages 434-444

  MacLean, David R ^a,e   Petrasovits, Andres ^b   Connelly, Philip W ^c   Joffres, Michel ^a   O'Connor, Brian ^d   Little, J Alick ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b HEALTH CANADA   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d North Shore Health Department   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Cholesterol; Coronary disease; Lipids; Lipoproteins; Population health; Triglycerides

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANADA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIET RESTRICTION; DYSLIPOPROTEINEMIA; FEMALE; HEALTH EDUCATION; HIGH RISK PATIENT; HUMAN; INTERVIEW; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; POPULATION RESEARCH; PUBLIC HEALTH; REFERENCE VALUE; STANDARDIZATION;

ADULT; AGE DISTRIBUTION; AGED; CANADA; FASTING; FEMALE; HUMANS; HYPERLIPOPROTEINEMIAS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; PREVALENCE; REFERENCE VALUES; RISK FACTORS; SEX DISTRIBUTION;

EID: 0032952650     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Heyden S. Epidemiology. In: Schettler FG, Boyd GS, eds. Atherosclerosis. Pathology, Physiology, Aetiology, Diagnosis and Clinical Management. New York: Elsevier Publishing Company, 1969:774-860.
2. Stamler J. Established major coronary risk factors. In: Marmot M, Elliot P, eds. Coronary Heart Disease Epidemiology. Oxford: Oxford University Press, 1992;88:1973-98.
3. Wilson PWF, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-41.
4. Triglyceride, high-density lipoprotein, and coronary heart disease. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. JAMA 1993;269:505-10.
5. The Lipid Research Clinics Coronary Primary Prevention Trial. I. Reduction in incidence of coronary heart disease. Lipid Research Clinics Program. JAMA 1984;251:351-64.
6. The Lipid Research Clinics Coronary Primary Prevention Trial. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Lipid Research Clinics Program. JAMA 1984;251:365-74.
7. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
8. Shepherd J, Cobbe M, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
9. Haskell W, Alderman E, Fain JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Program (SCRIP). Circulation 1994;89:975-90.
10. Puska P, Nissinen A, Tuomilehto J, et al. The community-based strategy to prevent coronary heart disease: conclusions from 10 years of the North Karelia Project. Annu Rev Public Health 1985;6:147-93.
11. Vartiainen E, Puska P, Pekkanen J, et al. Changes in risk factors explain changes in mortality from ischemic heart disease in Finland. BMJ 1994;309:23-37.
12. Tsevat J, Weinstein MC, Williams LW, Tosteson ANA, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991;83:1194-201.
13. The Expert Panel. Report on population strategies for blood cholesterol reduction: a statement from the National Cholesterol Education Program. Circulation 1991;83:2154-232.
14. Canadian Consensus Conference on Cholesterol: final report. The Canadian Consensus Conference on the Prevention of Heart and Vascular Disease by Altering Serum Cholesterol and Lipoprotein Risk Factors. CMAJ 1988;139(11 Suppl):1-8.
15. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
16. European Atherosclerosis Society Study Group. The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988;9:571-600.
17. Canadian Task Force on the Periodic Health Examination. The Canadian Guide to Clinical Preventive Health Care Examination. Ottawa: Minister of Supply and Services Canada, 1994.
18. Connelly PW, MacLean DR, Petrasovits A, et al. Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. CMAJ 1992;146:1977-87.
19. MacLean DR, Petrasovits A, Nargundkar M, et al. Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group. CMAJ 1992;146:1969-74.
20. Lipid and Lipoprotein Analysis. Manual of Laboratory Operation, Lipid Research Clinics Program [publ no 75-678]. Washington: US Dept of Health, Education, and Welfare, US Government Printing Office, 1982.
21. -. Clin Chem 1984;30:839-42.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of plasma low density lipoprotein cholesterol concentration without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
23. Laboratory Methods Committee of the Lipid Research Clinics Program. Cholesterol and triglyceride concentrations in serum/plasma pairs. Clin Chem 1977;23:60-3.
24. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA 1993;269:3002-8.
25. The Lipid Research Clinics Epidemiology Committee. Plasma lipid distribution in selected North American populations: The Lipid Research Clinics Program Prevalence Study. Circulation 1979;60:427-39.
26. Jones GJL, Hewitt D, Godin GJ, et al. Plasma lipoprotein levels and the prevalence of hyperlipoproteinemia in a Canadian working population. CMAJ 1980;122:37-46.
27. National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. Circulation 1991;83:2154-232.
28. Beaglehole R, LaRosa JC, Heiss G, et al. Serum cholesterol, diet, and the decline in coronary heart disease mortality. Prev Med 1979;8:538-47.
29. Burke GL, Sprafka JM, Folsen AR, et al. Trends in serum cholesterol levels from 1980 to 1987: the Minnesota heart survey. N Engl J Med 1991;324:941-6.
30. Sytkowski PA, Kannel WB, D'Agostine RB. Changes in risk factors and the decline in mortality from cardiovascular disease: the Framingham heart study. N Engl J Med 1990;322:1635-41.
31. Hewitt D, Jones GJL, Godin GJ, et al. Normative standards of plasma cholesterol and triglyceride concentrations in Canadians of working age. CMAJ 1977;117:1020-4.
32. Davis CE, Williams DH, Oganov RG, et al. Sex difference in high density lipoprotein cholesterol in six countries. J Epidemiol 1996;143:1100-6.
33. Grundy SM. Multifactorial etiology of hypercholesterolemia. ArteriosclerThromb 1991;11:1619-35.
34. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:2-14.
35. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986;112:432-7.
36. Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults: an update on guidelines from the Second Report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993;269:3009-14.
37. Reeder BA, Angel A, Ledoux M, Rabkin SW, Young TK, Sweet LE. Obesity and its relation to cardiovascular disease risk factors in Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ 1992;146:2009-19.
38. Frost PH, Davis BR, Burlando AJ, et al. Serum lipids and coronary heart disease in the elderly: findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation 1996:94:2381-8.
39. Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990;131:32-47.
40. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med 1995;332:1491-8.
41. Frohlich J, Fodor G, McPherson R, Genest J, Langner N. Rational for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: Interim report. Dyslipidemia Working Group of Health Canada. Can J Cardiol 1998;14(SupplA);17A-21A.
42. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971;74:1-12.
43. Blackburn H. Diet, and mass hyperlipidemia, a public health view. In: Levy R, ed. Nutrition, Lipids and Coronary Heart Disease. New York: Raven Press, 1979.
44. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
45. Bush TL, Fried LP, Barret-Connor E. Cholesterol, lipoproteins and coronary heart disease in women. Clin Chem 1988;34:860-70.
46. Castelli WP, Wilson PW, Levey D, Anderson K. Cardiovascular risk factors in the elderly. Am J Cardiol 1989;63:12H-9H.
47. Rose G. Strategy of prevention. Lessons from cardiovascular disease. BMJ 1981;i:1847-51.
48. Promoting Heart Health in Canada: A Focus on Cholesterol: Report of the Working Group on the Prevention and Control of Cardiovascular Disease. Ottawa: Federal-Provincial Advisory Committee on Community Health, Health Canada, 1992.
49. Tosteson ANA, Weinstein MC, Hunink MCM, et al. Cost-effectiveness of population wide educational approaches to reduce serum cholesterol levels. Circulation 1997;95:24-30.
50. Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for the primary and secondary prevention of coronary heart disease. JAMA 1991;265:1145-51.
51. Keys A, Menotti A, Karvonen MJ, et al. The diet and 15-year death rate in the seven countries study. Am J Epidemiol 1986;124:903-15.
52. Jenkins DJA. Optimal diet for reducing the risk of arteriosclerosis. Can J Cardiol 1995;11(Suppl G):118G-22G.